The medication program designed to monitor the risk of severe neutropenia is the Clozapine Risk Evaluation and Mitigation Strategy (REMS), a federally mandated safety program that applied to the antipsychotic drug clozapine. However, in a significant recent change, the FDA removed the Clozapine REMS program entirely. Clozapine remains the only psychiatric medication that carried this type of restricted distribution system specifically because of neutropenia risk.
What the Clozapine REMS Program Was
Clozapine is an antipsychotic used to treat schizophrenia that hasn’t responded to other medications. It’s widely considered the most effective drug for treatment-resistant schizophrenia, but it carries a unique risk: it can cause severe neutropenia, a dangerous drop in a type of white blood cell called neutrophils. Without enough neutrophils, the body loses its ability to fight infections, which can become life-threatening.
Because of this risk, the FDA created the Clozapine REMS in 2015 as a shared system covering all approved clozapine products. The program required prescribers, pharmacies, and patients to enroll in a restricted distribution network. Before a pharmacy could dispense clozapine, it had to verify that the patient’s blood work was current and that their white blood cell levels fell within safe ranges. Prescribers were required to submit absolute neutrophil count (ANC) results to the REMS program, and pharmacists had to confirm patient eligibility before filling each prescription.
Why Neutropenia Monitoring Matters
Severe neutropenia from clozapine, historically called agranulocytosis, is estimated to occur in about 1 to 2 percent of treated patients. A large U.S. study published in the New England Journal of Medicine found the cumulative incidence was 0.80 percent at one year and 0.91 percent at a year and a half. That study identified 73 patients who developed agranulocytosis, two of whom died from infectious complications. The risk is relatively low in absolute terms, but the consequences can be fatal, which is why monitoring became mandatory decades ago.
The condition is tracked through a simple blood test measuring the absolute neutrophil count. In some monitoring systems, an ANC below 2,000 cells per microliter triggers more frequent testing (twice per week), while an ANC below 1,500 cells per microliter has historically been the threshold for stopping clozapine. When the REMS was established, it set a lower threshold for considering cessation at 1,000 cells per microliter, aligning with the definition of severe neutropenia used in blood disorder medicine.
The Required Blood Test Schedule
Under the monitoring guidelines that accompanied clozapine prescribing, the FDA required weekly blood draws during the first six months of treatment. If the ANC stayed at or above 1,500 cells per microliter throughout that period, testing could drop to every two weeks for the next six months. After a full year of stable counts, monitoring shifted to once a month for the duration of treatment.
This schedule was one of the biggest practical barriers to clozapine use. Patients needed reliable transportation to labs, consistent follow-through on appointments, and the willingness to have blood drawn on a rigid schedule. Missing a blood test could mean a gap in medication, which for someone with treatment-resistant schizophrenia could trigger a relapse. Many clinicians and researchers have argued that the monitoring burden caused clozapine to be significantly underused relative to its clinical benefits.
Adjusted Thresholds for Benign Ethnic Neutropenia
People of African, Middle Eastern, or West Indian descent commonly have naturally lower neutrophil counts, a condition called benign ethnic neutropenia (BEN). Their baseline ANC typically falls between 1,000 and 1,800 cells per microliter. This isn’t associated with more frequent infections or a higher risk of clozapine-induced blood problems, but it does mean their counts can dip below standard thresholds even when nothing is wrong.
To account for this, the monitoring system used a separate set of criteria. Patients with BEN needed at least two baseline ANC measurements before starting treatment. The threshold for severe neutropenia requiring treatment interruption was set lower, at 500 cells per microliter rather than 1,000. If their count dropped into the 500 to 999 range, treatment could continue with more frequent monitoring (three times per week) and a hematology consultation, sometimes alongside lithium to help boost white cell production. A recent global expert panel reinforced this approach, recommending a cessation threshold of 500 cells per microliter for individuals with the genetic variant responsible for BEN.
The FDA’s Removal of the REMS
The FDA has now removed the Clozapine REMS program. This means prescribers no longer need to enroll in the program or register their patients. They are not required to submit ANC results to a central database. Pharmacies no longer need REMS enrollment to order clozapine from distributors, and pharmacists no longer need to verify patient eligibility or ANC monitoring status before dispensing the medication.
This does not mean blood monitoring is no longer recommended. The clozapine prescribing label still carries warnings about severe neutropenia, and standard clinical practice calls for ongoing ANC monitoring. What changed is the enforcement mechanism: the centralized system that required every prescription to pass through a verification checkpoint has been dismantled. The responsibility for monitoring now falls more directly on the prescribing clinician and the patient, rather than being gatekept at the pharmacy level.
Restarting Clozapine After Neutropenia
If a patient’s neutrophil count drops low enough to require stopping clozapine, restarting the drug is possible but requires careful planning. Under the previous REMS framework, a patient who experienced severe neutropenia could not simply resume treatment on their own prescriber’s authority. The decision involves understanding what caused the drop, whether the neutropenia was actually drug-related or had another explanation, and what protective strategies might reduce the risk of recurrence.
Clinicians have used several approaches to safely restart clozapine in patients who experienced neutropenia. These include medications that stimulate white blood cell production, lithium supplementation to raise neutrophil counts, and close “watch and wait” monitoring with frequent blood draws. A case series from a high-security forensic hospital found that even in patients with prior neutropenia episodes, clozapine could be safely restarted with these precautions, resulting in significant clinical improvement. For patients with treatment-resistant schizophrenia, where clozapine is often the only medication that provides meaningful relief, the benefit of rechallenge can outweigh the risk when managed carefully.